OBJECTIVE: To evaluate the demographic characteristics, clinical course, and outcome in organ transplant recipients with metastatic skin cancer. DESIGN AND SETTING: An international, multicenter, Internet-coordinated collaborative group retrospectively analyzed data from 68 organ transplant recipients with 73 distinct metastatic skin cancers. MAIN OUTCOME MEASUREMENTS: The Kaplan-Meier method was used to estimate the cumulative incidence of relapse, overall survival, and disease-specific survival after metastatic skin cancer. Univariate Cox proportional hazards models were fit to evaluate factors for an association with survival. RESULTS: Metastasis from skin cancer in organ transplant recipients most commonly consisted of squamous cell carcinoma in regional nodal basins. It was predominantly treated with a combination of surgery and irradiation. By 1 year after metastasis, the cumulative incidence of relapse was 29%, and the 3-year disease-specific survival was 56%. Patients whose initial metastases were distant or systemic had a significantly poorer disease-specific survival than those whose initial metastases were in-transit or regional (risk ratio, 6.5; P<.001). CONCLUSIONS: Metastatic skin cancer in organ transplant recipients has a poor prognosis. Preventive, early, and aggressive therapeutic interventions are required to minimize this serious complication of transplant-associated immunosuppression.
OBJECTIVE: To evaluate the demographic characteristics, clinical course, and outcome in organ transplant recipients with metastatic skin cancer. DESIGN AND SETTING: An international, multicenter, Internet-coordinated collaborative group retrospectively analyzed data from 68 organ transplant recipients with 73 distinct metastatic skin cancers. MAIN OUTCOME MEASUREMENTS: The Kaplan-Meier method was used to estimate the cumulative incidence of relapse, overall survival, and disease-specific survival after metastatic skin cancer. Univariate Cox proportional hazards models were fit to evaluate factors for an association with survival. RESULTS: Metastasis from skin cancer in organ transplant recipients most commonly consisted of squamous cell carcinoma in regional nodal basins. It was predominantly treated with a combination of surgery and irradiation. By 1 year after metastasis, the cumulative incidence of relapse was 29%, and the 3-year disease-specific survival was 56%. Patients whose initial metastases were distant or systemic had a significantly poorer disease-specific survival than those whose initial metastases were in-transit or regional (risk ratio, 6.5; P<.001). CONCLUSIONS:Metastatic skin cancer in organ transplant recipients has a poor prognosis. Preventive, early, and aggressive therapeutic interventions are required to minimize this serious complication of transplant-associated immunosuppression.
Authors: Joana Lanz; Jan Nico Bouwes Bavinck; Marlies Westhuis; Koen D Quint; Catherine A Harwood; Shaaira Nasir; Vanessa Van-de-Velde; Charlotte M Proby; Carlos Ferrándiz; Roel E Genders; Véronique Del Marmol; Giulia Forchetti; Jürg Hafner; Domenic G Vital; Guenther F L Hofbauer Journal: JAMA Dermatol Date: 2019-01-01 Impact factor: 10.282
Authors: Yvonne Y Li; Glenn J Hanna; Alvaro C Laga; Robert I Haddad; Jochen H Lorch; Peter S Hammerman Journal: Clin Cancer Res Date: 2015-01-14 Impact factor: 12.531
Authors: Robert P Carroll; David San Segundo; Kevin Hollowood; Teresa Marafioti; Taane G Clark; Paul N Harden; Kathryn J Wood Journal: J Am Soc Nephrol Date: 2010-01-28 Impact factor: 10.121
Authors: Sharifeh Farasat; Siegrid S Yu; Victor A Neel; Kishwer S Nehal; Thomas Lardaro; Martin C Mihm; David R Byrd; Charles M Balch; Joseph A Califano; Alice Y Chuang; William H Sharfman; Jatin P Shah; Paul Nghiem; Clark C Otley; Anthony P Tufaro; Timothy M Johnson; Arthur J Sober; Nanette J Liégeois Journal: J Am Acad Dermatol Date: 2011-01-20 Impact factor: 11.527